COVID-19 Vaccination Associated With Reduced Postoperative SARS-CoV-2 Infection and Morbidity

  • Nikhil K. Prasad
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
  • Rachel Lake
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
  • Brian R. Englum
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
  • Douglas J. Turner
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
  • Tariq Siddiqui
    Surgery Service, Veterans Affairs Medical Centre, Baltimore, MD
  • Minerva Mayorga-Carlin
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD
  • John D. Sorkin
    Geriatrics Research, Education, and Clinical Center, Veterans Affairs Medical Centre, Baltimore, MD
  • Brajesh K. Lal
    Department of Surgery, University of Maryland School of Medicine, Baltimore, MD

説明

<jats:sec> <jats:title>Objective:</jats:title> <jats:p>The purpose of this study was to determine the effect of COVID-19 vaccination on postoperative mortality, pulmonary and thrombotic complications, readmissions and hospital lengths of stay among patients undergoing surgery in the United States.</jats:p> </jats:sec> <jats:sec> <jats:title>Background:</jats:title> <jats:p>While vaccination prevents COVID-19, little is known about its impact on postoperative complications.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>This is a nationwide observational cohort study of all 1,255 Veterans Affairs facilities nationwide. We compared patients undergoing surgery at least 2 weeks after their second dose of the Pfizer BioNTech or Moderna vaccines, to contemporary propensity score matched controls. Primary endpoints were 30-day mortality and postoperative COVID-19 infection. Secondary endpoints were pulmonary or thrombotic complications, readmissions, and hospital lengths of stay.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>30,681 patients met inclusion criteria. After matching, there were 3,104 in the vaccination group (1,903 received the Pfizer BioNTech, and 1,201 received the Moderna vaccine) and 7,438 controls. Full COVID-19 vaccination was associated with lower rates of postoperative 30-day COVID-19 infection (Incidence Rate Ratio and 95% confidence intervals, 0.09 [0.01,0.44]), pulmonary complications (0.54 [0.39, 0.72]), thrombotic complications (0.68 [0.46, 0.99]) and decreased hospital lengths of stay (0.78 [0.69, 0.89]). Complications were also low in vaccinated patients who tested COVID-19 positive before surgery but events were too few to detect a significant difference compared to controls.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>COVID-19 vaccination is associated with lower rates of postoperative morbidity. The benefit is most pronounced among individuals who have never had a COVID-19 infection before surgery.</jats:p> </jats:sec>

収録刊行物

  • Annals of Surgery

    Annals of Surgery 275 (1), 31-36, 2021-08-19

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ